• AstraZeneca Zinforo™

How do you tell people how to implement a European brand of antibiotics?

Zinforo™ (ceftaroline fosamil), is a new intravenous cephalosporin antibiotic, for adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP). It is the only approved cephalosporin monotherapy in Europe with demonstrated clinical efficacy against methicillin-resistant Staphylococcus aureus (MRSA), a common cause of serious and difficult to treat complicated skin infections.

AstraZeneca commissioned PITCH&CO to create a set of brand guidelines to control the implementation of this exciting new brand of antibiotics. PITCH also designed and produced five multi-page training modules for this product.